Overview

Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant Recipients

Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effect of conversion from calcineurin inhibitor to sirolimus based therapy on renal function.
Phase:
Phase 3
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Calcineurin Inhibitors
Cyclosporine
Cyclosporins
Everolimus
Sirolimus
Tacrolimus